Homology Medicines (BATS:FIXX) CFO Lee Kalowski Sells 3,972 Shares

Homology Medicines, Inc. (BATS:FIXXGet Free Report) CFO Lee Kalowski sold 3,972 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32. Following the completion of the transaction, the chief financial officer directly owned 138,471 shares of the company’s stock, valued at approximately $2,293,079.76. This represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Homology Medicines Price Performance

Shares of FIXX opened at $12.73 on Friday. Homology Medicines, Inc. has a 1-year low of $12.02 and a 1-year high of $14.30.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.

Featured Stories

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.